Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
Source: View publication →
The HERS trial demonstrated that continuous combined hormone replacement therapy does not reduce the overall risk of subsequent cardiovascular events in postmenopausal women with established coronary disease and instead increases the risk of venous thromboembolism.
Key Findings
Study Design
Study Limitations
Clinical Significance
HERS fundamentally challenged prevailing medical practice by providing definitive randomized data that continuous combined hormone replacement therapy does not offer cardiovascular protection for women with established heart disease, prompting clinical guidelines to strongly advise against initiating HRT for the secondary prevention of coronary heart disease.
Historical Context
Prior to HERS, large observational studies overwhelmingly suggested that postmenopausal women taking hormone replacement therapy had a 30% to 50% lower risk of CHD, leading to widespread off-label prescribing for cardiovascular protection. HERS was the first large-scale, randomized, blinded clinical trial to formally test this hypothesis in secondary prevention. Its surprising negative findings and early harm signal were initially met with skepticism but were later definitively corroborated in the primary prevention setting by the landmark Women's Health Initiative (WHI) trial in 2002, permanently shifting the paradigm of postmenopausal medicine.
Guided Discussion
High-yield insights from every perspective
Before the HERS trial, hormone replacement therapy was widely believed to be cardioprotective based on observational data and surrogate markers. What were the physiological mechanisms and surrogate lipid markers that led to this belief, and what does the HERS trial teach us about relying on surrogate endpoints?
Key Response
HRT lowers LDL and raises HDL, leading early researchers to assume cardioprotection. HERS demonstrated that positive effects on surrogate markers (lipids) do not always translate to improved clinical outcomes, emphasizing the need for randomized controlled trials measuring hard clinical endpoints like myocardial infarction and death.
A 65-year-old postmenopausal woman with a history of a myocardial infarction two years ago asks if she should start combined estrogen and progestin therapy for hot flashes. Based on the HERS trial findings, how would you counsel her regarding the cardiovascular and thrombotic risks?
Key Response
The HERS trial showed that initiating continuous combined hormone therapy in women with established coronary disease does not reduce the overall risk of CHD events and significantly increases the risk of venous thromboembolism (VTE) and gallbladder disease, especially in the first year. Therefore, it is contraindicated for secondary prevention of CHD.
The HERS trial reported a notable time-varying effect of HRT on cardiovascular events, with an early increase in risk and a later decrease. How does this biphasic pattern influence the decision to continue or stop therapy in a patient who has already been on HRT for several years without incident?
Key Response
The trial showed an increased risk of CHD events in year 1, but a trend toward decreased risk in years 3 to 5. While the HERS authors recommended not initiating HRT for secondary prevention, they suggested it might be reasonable for women already tolerating HRT for over a year to continue, given the potential late benefits and the passing of the early high-risk window for thrombosis and plaque rupture.
The HERS trial represents a classic example of a large randomized controlled trial overturning entrenched clinical dogma based on observational data. How do we explain the discrepancy between the protective effect of HRT seen in earlier observational studies (like the Nurses' Health Study) and the null/harmful effect seen in HERS, and how should this shape our approach to adopting new therapies?
Key Response
The discrepancy is largely attributed to healthy user bias and confounding in observational cohorts where women taking HRT were generally healthier, more compliant, and had higher socioeconomic status. HERS highlights the critical importance of randomized controlled trials (RCTs) to eliminate hidden confounders before widely recommending therapies for prevention, profoundly shaping modern evidence-based cardiology.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In the HERS trial, adherence to the study drug dropped to 82 percent at 1 year and 75 percent at 3 years. Given the biphasic time-to-event curves that violate the proportional hazards assumption, how might a per-protocol or inverse probability weighting analysis impact the interpretation of the late-phase cardiovascular outcomes compared to the standard intention-to-treat analysis?
Key Response
High drop-out and non-adherence can dilute the treatment effect in an intention-to-treat (ITT) analysis. Furthermore, crossing survival curves (early harm, late benefit) violate the Cox proportional hazards assumption. A methodologist must consider time-dependent covariates or specialized modeling (like restricted mean survival time) to more accurately quantify the biphasic biological effect, though ITT remains the standard for assessing real-world clinical effectiveness.
As an editor reviewing the HERS manuscript, how would you evaluate the generalizability of the findings given the specific use of conjugated equine estrogens (CEE) 0.625 mg and medroxyprogesterone acetate (MPA) 2.5 mg, and what caveats would you demand the authors include regarding different formulations, doses, or routes of administration?
Key Response
A critical reviewer would flag that HERS tested only one specific continuous combined oral regimen. The first-pass hepatic effect of oral estrogens increases procoagulant factors, driving early VTE and MI risk. Transdermal preparations or different progestins might have completely different risk profiles. The editor must ensure the conclusions are carefully scoped to the tested regimen rather than broadly condemning all forms of hormone therapy.
How did the findings of the HERS trial, later corroborated by the Women's Health Initiative (WHI), specifically alter AHA/ACC secondary prevention guidelines for coronary artery disease, and what is the current Class of Recommendation and Level of Evidence for initiating hormone therapy for cardiovascular protection?
Key Response
HERS provided the first definitive RCT evidence that HRT should not be used for secondary prevention, leading the AHA/ACC to issue guidelines explicitly recommending against initiating HRT for the purpose of preventing cardiovascular disease (Class III: Harm, Level of Evidence A). It forced a complete reversal of prior permissive guidelines that had been based on observational data, cementing the mandate that HRT is indicated only for severe menopausal symptoms and not for cardioprotection.
Clinical Landscape
Noteworthy Related Trials
Estrogen Replacement and Atherosclerosis (ERA) Trial
Tested
Conjugated equine estrogens alone or with medroxyprogesterone acetate
Population
Postmenopausal women with angiographically verified coronary disease
Comparator
Placebo
Endpoint
Angiographic progression of coronary atherosclerosis
Women's Health Initiative (WHI) Estrogen plus Progestin Trial
Tested
Conjugated equine estrogens (CEE) 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg daily
Population
Healthy postmenopausal women with an intact uterus
Comparator
Placebo
Endpoint
Coronary heart disease (nonfatal MI or CHD death) and invasive breast cancer
Women's Health Initiative (WHI) Estrogen-Alone Trial
Tested
Conjugated equine estrogens (CEE) 0.625 mg daily
Population
Healthy postmenopausal women with prior hysterectomy
Comparator
Placebo
Endpoint
Coronary heart disease and invasive breast cancer
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis